On a positive Note8 Jan 2019 12:10
https://www.pfizer.com/partnering/areas_of_interest/oncology
We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:
Lung, colorectal, breast, ovarian, renal, and hematologic cancers
Cancers prevalent in Asia (e.g., gastric cancer, hepatocellular carcinoma)
Specific areas of interest include:
Targets and technologies that enable antibody and ADC approaches
Oncogenic signaling mechanisms
Tumor metabolism
Epigenetics
Small molecule immuno modulators
Directed tumor cell killing via immune-based mechanisms
Precision medicine
Functional genomics
Liquid biopsy technologies
Technologies that deliver drugs asymmetrically to specific tissues
Targeted nanoparticle technologies and assets
Immuno-Oncology
The recent clinical successes reported with cancer immunotherapy are reshaping the field of oncology. Pfizer plans to significantly advance its leadership in this area by partnering to develop cutting edge science beyond the current mainstream immune checkpoints, e.g., CAR-T, vaccinia, and small molecules. The IO programs at Pfizer uniquely leverage a combination of our scientific and clinical strength in immuno-biology alongside our historical expertise in developing first-in-class cancer and vaccine therapies.
Pfizer’s efforts in IO include external collaborative alliances with leading academic medical centers (e.g., MD Anderson) and visionary biotech firms (e.g., Cellectis). Our IO efforts are driven primarily within our Rinat laboratory site in South San Francisco, CA. Leveraging its strength in biotherapeutics alongside core expertise in immuno-biology, Rinat has a strong record of converting validated targets into novel protein-based therapeutics, and advancing molecular and cell-based IO treatments. We would like to partner in the IO space on pre-clinical and clinical stage antibody and small molecule-based immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor infiltrating lymphocyte cell populations.
We are interested in establishing alliances to develop and access:
Novel Targets for Overcoming Tumor-induced Immune Resistance
Targets that promote immune response whether alone or in combination with checkpoint inhibitors
Targets that provide Innate immune support/ activation
Targets that reduce immune suppressionCell-based Therapies
CAR-T, TCR, and other hybrid targeting modalities with a focus on allogeneic approaches
Platform Technologies
Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising combination therapies
New modalities to induce immune responses: Bi-specific mAbs, nanoparticles, oncolytic viruses, tumor vaccines, chimeric antigen receptors (CARs), or novel T cell receptors (TCRs)
Identification of new immune modulating targets
Monitoring of immune-supporting and immune-suppressing biomarkers within the tumor as wel
Sign In
Follow the stocks
